Verona Pharma VRNA 2022 Respiratory Therapy Investor Presentation

Verona Pharma plc presents ensifentrine, a Phase 3 first-in-class inhaled dual PDE3/PDE4 inhibitor for maintenance treatment of COPD. The presentation highlights positive ENHANCE-2 clinical data, a large ~$10B US market opportunity, and significant unmet need among symptomatic patients despite existing dual/triple therapies.